| SARS-CoV-2 vaccine | Sinovac Research and Development Co., Ltd. | Inactivated | Phase 3 |
| Inactivated SARS-CoV-2 vaccine | Sinopharm + China National Biotec Group Co. Ltd. + Wuhan Institute of Biological Products | Inactivated | Phase 3 |
| Inactivated SARS-CoV-2 vaccine | Sinopharm + China National Biotec Group Co. Ltd. + Beijing Institute of Biological Products | Inactivated | Phase 3 |
| ChAdOx1-S (AZD1222) | AstraZeneca + University of Oxford | Viral vector | Phase 3 |
| Recombinant novel coronavirus vaccine (adenovirus type 5 vector) | CanSino Biologics Inc. + Beijing Institute of Biotechnology | Viral vector | Phase 3 |
| Gam-COVID-Vac, Aden-based (rAd26-S+rAd5-S) | Gamaleya Research Institute, Health Ministry of the Russian Federation | Viral vector | Phase 3 |
| AD26.COV2.S | Janssen Pharmaceuticals, Inc. | Viral vector | Phase 3 |
| SARS-CoV-2 rS/Matrix M1-Adjuvant | Novavax | Protein subunit | Phase 3 |
| mRNA-1273 | Moderna + National Institute of Allergy and Infectious Diseases | RNA | Phase 3 |
| BNT162 (3 LNP-mRNAs) | BioNTech + Fosun Pharma; Jiangsu Provincial Centre for Disease Prevention and Control + Pfizer | RNA | Phase 2/3 |
| Recombinant SARS-CoV-2 vaccine | Anhui Zhifei Longcom Biopharmaceuticals + Institute of Microbiology, Chinese Academy of Sciences | Protein subunit | Phase 3 |
| CVnCoV vaccine | CureVac AG | RNA | Phase 3 |
| SARS-CoV-2 vaccine | Institute of Medical Biology, Chinese Academy of Medical Sciences | Inactivated | Phase 3 |
| QazCovid-in - COVID-19 inactivated vaccine | Research Institute for Biological Safety Problems, Republic of Kazakhstan | Inactivated | Phase 3 |
| INO-4800+electroporation | Inovio Pharmaceuticals + International Vaccine Institute, South Korea + Advaccine (Suzhou) Biopharmaceutical Co., Ltd. | DNA | Phase 2/3 |
| AG0301-COVID19 | AnGes + Takara Bio Inc. + Osaka University | DNA | Phase 2/3 |
| nCov vaccine | Cadila Healthcare Ltd. | DNA | Phase 3 |
| GX-19 | Genexine Consortium | DNA | Phase 1/2 |
| Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) | Bharat Biotech International Limited | Inactivated | Phase 3 |
| KBP-COVID-19 (RBD-based) | Kentucky Bioprocessing Inc. | Protein subunit | Phase 1/2 |
| SARS-CoV-2 vaccine formulation 1 with adjuvant | Sanofi Pasteur + GSK | Protein subunit | Phase 1/2 |
| ARCT-021 | Arcturus Therapeutics | RNA | Phase 2 |
| RBD SARS-CoV-2 HBsAg VLP vaccine | Serum Institute of India + Accelagen Pty | Virus like particle | Phase 1/2 |
| Inactivated SARS-CoV-2 vaccine | Shenzhen Kangtai Biological Products Co., Ltd. | Inactivated | Phase 2 |
| GRAd-COV2 | ReiThera + Leukocare + Univercells | Viral vector | Phase 1 |
| VXA-CoV2-1 AD5 adjuvanted oral vaccine platform | Vaxart Inc. | Viral vector | Phase 1 |
| MVA-SARS-2-S | University Medical Centre Hamburg-Eppendorf + Ludwig Maximilian University of Munich | Viral vector | Phase 2 |
| SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant | Clover Biopharmaceuticals Inc./GSK/Dynavax | Protein subunit | Phase 2/3 |
| COVID19 vaccine | Vaxine Pty Ltd. + Medytox | Protein subunit | Phase 1 |
| MVC-COV1901 (S-2P protein + CpG 1018) | Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases | Protein subunit | Phase 1 |
| FINLAY-FR anti-SARS-CoV-2 Vaccine | Instituto Finlay de Vacunas | Protein subunit | Phase 2 |
| EpiVacCorona | Federal Budgetary Research Institution, State Research Centre of Virology and Biotechnology “Vector” | Protein subunit | Phase 1/2 |
| RBD Recombinant SARS-CoV-2 vaccine (Sf9 cell) | West China Hospital of Sichuan University | Protein subunit | Phase 2 |
| IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) | University Hospital Tübingen | Protein subunit | Phase 1 |
| UB-612 | COVAXX + United Biomedical Inc. | Protein subunit | Phase 2/3 |
| V591-001 - Measles-vector based (TMV-o38) | Merck & Co. Inc. + Themis + Merck Sharp & Dohme Ltd. + Institut Pasteur + University of Pittsburgh | Viral vector (replicating) | Phase 1/2 |
| DelNS1-2019-nCoV-RBD-OPT1 | Jiangsu Provincial Centre for Disease Prevention and Control | Viral vector (replicating) | Phase 2 |
| LNP-nCoVsaRNA | Imperial College London | RNA | Phase 1 |
| SARS-CoV-2 mRNA vaccine | Shulan Hospital + Guangxi Centre for Disease Prevention and Control | RNA | Phase 1 |
| Coronavirus-like particle COVID-19 | Medicago Inc. | Viral like particle | Phase 2/3 |
| Covid-19/aAPC vaccine | Shenzhen Geno-Immune Medical Institute | Viral vector (replicating) + APC | Phase 1 |
| LV-SMENP-DC vaccine | Shenzhen Geno-Immune Medical Institute | Viral vector (non-replicating) + APC | Phase 1/2 |
| AdimrSC-2f | Adimmune Corporation | Protein subunit | Phase 1 |
| Covigenix VAX-001 | Entos Pharmaceuticals Inc. | DNA | Phase 1 |
| CORVax | Providence Health & Services | DNA | Phase 1 |
| ChulaCov19 mRNA vaccine | Chulalongkorn University | RNA | Phase 1 |
| bacTRL-Spike | Symvivo Corporation | DNA | Phase 1 |
| hAd5-S-Fusion+N-ETSD vaccine | ImmunityBio, Inc. | Viral vector | Phase 1 |
| COH04S1 (MVA-SARS-2-S) | City of Hope Medical Center + National Cancer Institute | Viral vector | Phase 1 |
| rVSV-SARS-CoV-2-S vaccine | Israel Institute for Biological Research | Viral vector (replicating) | Phase 1/2 |
| Dendritic cell vaccine AV-COVID-19 | Avita Biomedical, Inc. + National Institute of Health Research and Development, Ministry of Health, Republic of Indonesia | Viral vector (replicating) + APC | Phase 1/2 |
| COVI-VAC | Codagenix/Serum Institute of India | Live attenuated virus | Phase 1 |
| CIGB-669 (RBD+AgnHB) | Center for Genetic Engineering and Biotechnology | Protein subunit | Phase 1/2 |
| CIGB-66 (RBD + aluminium hydroxide) | Center for Genetic Engineering and Biotechnology | Protein subunit | Phase 1/2 |
| VLA2001 | Valneva + National Institute for Health Research, United Kingdom | Inactivated | Phase 1/2 |
| BECOV2 | Biological E., Ltd. | Protein subunit | Phase 1/2 |
| AdCLD-CoV19 | Cellid Co. Ltd. | Viral vector (replicating) | Phase 1/2 |
| GLS-5310 | GeneOne Life Science, Inc. | DNA | Phase 1/2 |
| Recombinant SARS-CoV-2 spike protein, aluminium adjuvanted | Nanogen Pharmaceutical Biotechnology | Protein subunit | Phase 1/2 |
| S-268019 | Shionogi Co., Ltd. | Protein subunit | Phase 1/2 |
| AdCOVID | Altimmune, Inc. | Viral vector | Phase 1 |
| SARS-CoV-2-RBD-Fc fusion protein | University Medical Center Groningen + Akston Biosciences Inc. | Protein subunit | Phase 1/2 |
| ERUCOV-VAC | Erciyes University | Inactivated | Phase 1 |